PHILADELPHIA--(BUSINESS WIRE)--Vivodyne, a biotech that discovers and develops more effective drugs by testing them on lab-grown human organs, today announced the close of $38 million in total seed ...

95% of clinical trials fail because animal testing is no substitute for human biology - Vivodyne’s robotics platform grows thousands of human tissues daily, directly tackling the biological gap behind ...

Khosla Ventures-backed Vivodyne is growing human tissues in the lab to test potential new therapies before they go to clinical trials. Only about 10% of drugs in development ever make it to market.

Stem Pharm, a Madison biotech startup, is using lab-created 3D "organoids" to develop a treatment for Alzheimer's disease. In April, the FDA and NIH announced plans to incentivize so-called "new ...

Vivodyne has launched with $38 million in seed funding, led by the investment firm Khosla Ventures, to discover and develop drugs by testing them on lab-grown human organs. The Philadelphia-based ...

BOSTON - What's in a breed? Turns out pet owners are willing to shell out a lot to find out. Market research shows pet DNA testing is a more than $345 million industry on track to jump 85% by 2030.